Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis

Shock

Volumn 26, Issue 1, 2006, Pages 41-49

  Gomes, Rachel N ^a   Bozza, Fernando A ^b   Amâncio, Rodrigo T ^a   Japiassú, André M ^b   Vianna, Rosa C S ^b   Larangeira, Andréa P ^a   Gouvêa, Juliana M ^a   Bastos, Marcela S ^a   Zimmerman, Guy A ^c   Stafforini, Diana M ^d   Prescott, Stephen M ^d   Bozza, Patrícia T ^a   Castro Faria Neto, Hugo C ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Cytokines; PAF; PAF AH; Sepsis; SIRS

Indexed keywords

ANTIBIOTIC AGENT; IMIPENEM; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PAFASE; RECOMBINANT ENZYME; RECOMBINANT PLATELET ACTIVATING FACTOR ACETYLHYDROLASE; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIINFECTIVE AGENT; CYTOKINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DEATH; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUSE; NONHUMAN; PERITONEAL FLUID; SEPSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ANIMAL; BLOOD; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG COMBINATION; MIDDLE AGED;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ANTI-BACTERIAL AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; PLATELET ACTIVATING FACTOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 33747199084     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000209562.00070.1a     Document Type: Article

References (43)

1. Angus DC, Wax RS: Epidemiology of sepsis: an update. Crit Care Med 29:S109-S116, 2001.
2. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150, 2003.
3. Cohen J: The immunopathogenesis of sepsis. Nature 420:885-891, 2002.
4. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250-1256, 2003.
5. Glauser MP, Zanetti G, Baumgartner JD, et al: Septic shock: pathogenesis. Lancet 338:732-736, 1991.
6. Lopez Diez F, Nieto ML, Fernandez-Gallardo S, et al: Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest 83:1733-1740, 1989.
7. Zimmerman GA, McIntyre TM, Prescott SM, et al: The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 30:S294-S301, 2002.
8. Imaizumi TA, Stafforini DM, Yamada Y, et al: Platelet-activating factor: a mediator for clinicians. J Intern Med 238:5-20, 1995.
9. Chang SW, Feddersen CO, Henson PM, et al: Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 79:1498-1509, 1987.
10. Marshall JC: Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2:391-405, 2003.
11. Stafforini DM, McIntyre TM, Zimmerman GA, et al: Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 40:643-672, 2003.
12. Cao Y, Stafforini DM, Zimmerman GA, et al: Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem 273:4012-4020, 1998.
13. Tjoelker LW, Eberhardt C, Unger J, et al: Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J Biol Chem 270:25481-25487, 1995.
14. Schuster DP, Metzler M, Opal S, et al: Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 31:1612-1619, 2003.
15. Opal S, Laterre PF, Abraham E, et al: Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 32:332-341, 2004.
16. Pacheco P, Bozza FA, Gomes RN, et al: Lipopolysaccharide-induced leukocyte lipid body formation in vivo: innate immunity elicited intracellular loci involved in eicosanoid metabolism. J Immunol 169:6498-6506, 2002.
17. Castro-Faria-Neto HC, Bozza PT, Martins MA, et al: Platelet mobilization induced by PAF and its role in the thrombocytosis triggered by adrenaline in rats. Thromb Haemost 62:1107-1111, 1989.
18. Vianna RCS, Gomes RN, Bozza FA, Amâncio RT, et al: Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 21:115-120, 2004.
19. Hack CE, Aarden LA, Thijs LG: Role of cytokines in sepsis. Adv Immunol 66:101-195, 1997.
20. Zisman DA, Kunkel SL, Strieter RM, et al: MCP-1 protects mice in lethal endotoxemia. J Clin Invest 99:2832-2836, 1997.
21. Lu B, Rutledge BJ, Gu L, Fiorillo J, et al: Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 187:601-608, 1998.
22. Grissom CK, Orme JF Jr., Richer LD, et al: Platelet-activating factor acetylhydrolase is increased in lung lavage fluid from patients with acute respiratory distress syndrome. Crit Care Med 31:770-775, 2003.
23. Claus RA, Russwurm S, Dohrn B, et al: Plasma platelet-activating factor acetylhydrolase activity in critically ill patients. Crit Care Med 33: 1416-1419, 2005.
24. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shock - a review of laboratory models and a proposal. J Surg Res 29:189-201, 1980.
25. Hubbard WJ, Choudhry M, Schwacha MG, et al: Cecal ligation and puncture. Shock 24(1):52-57, 2005.
26. Remick DG, Ward PA: Evaluation of endotoxin models for the study of sepsis. Shock 24(1):7-11, 2005.
27. van der Poll T: Immunotherapy of sepsis. Lancet Infect Dis 1:165-174, 2001.
28. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 22:1720-1728, 1994.
29. Kruse-Elliott KT, Albert DH, Summers JB, et al: Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist. Shock 5:265-273, 1996.
30. Tjoelker LW, Wilder C, Eberhardt C, et al: Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374:549-553, 1995.
31. Marathe GK, Davies SS, Harrison KA, et al: Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J Biol Chem 274:28395-28404, 1999.
32. Stafforini DM, Tjoelker LW, McCormick SP, et al: Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 274:7018-7024, 1999.
33. Graham RM, Stephens CJ, Silvester W, et al: Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med 22:204-212, 1994.
34. Tetta C, Bussolino F, Modena V, et al: Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Immunol 91:244-256, 1990.
35. Caplan MS, Hsueh W: Necrotizing enterocolitis: role of platelet activating factor, endotoxin, and tumor necrosis factor. J Pediatr 117:S47-S51, 1990.
36. Stafforini DM, Numao T, Tsodikov A, et al: Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest 103:989-997, 1999.
37. Narahara H, Nishioka Y, Johnston JM: Secretion of platelet-activating factor acetylhydrolase by human decidual macrophages. J Clin Endocrinol Metab 77:1258-1262, 1993.
38. Memon RA, Fuller J, Moser AH, et al: In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am J Physiol 277:R94-R103, 1999.
39. Hack CE, De Groot ER, Felt-Bersma RJ, et al: Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704-1710, 1989.
40. Matsukawa A, Hogaboam CM, Lukacs NW, et al: Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J Immunol 163:6148-6154, 1999.
41. Calandra T, Echtenacher B, Roy DL, et al: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164-170, 2000.
42. Roger T, David J, Glauser MP, et al: MIF regulates innate immune responses through modulation of toll-like receptor 4. Nature 414:920-924, 2001.
43. Bozza FA, Gomes RN, Japiassu AM, et al: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22:309-313, 2004.